Synapse - Gregory Riely

Results (599)

Hematology and oncology pearls

Book Whole

Mosby Elsevier (2005)

Clinical characteristics and natural history of patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations treated with erlotinib or gefitinib

Meeting Abstract

Riely, G. J.; Miller, V. A.; Pao, W.; Zakowski, M.; Ladanyi, M.; Heelan, R. T.; Kris, M. G.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

Estimation of the likelihood of epidermal growth factor receptor (EGFR) mutations based on cigarette smoking history in patients with adenocarcinoma of the lung

Meeting Abstract

Pham, D.; Kris, M. G.; McDonough, T.; Riely, G. J.; Venkatraman, E. S.; Pao, W.; Wilson, R. K.; Miller, V. A.; Singh, B.; Rusch, V. W.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

EGFR mutation, immumohistochemistry (IHC) and chromogenic in situ hybridization (CISH) as predictors of sensitivity to erlotinib and gefitinib in patients (pts) with NSCLC

Meeting Abstract

Miller, V. A.; Zakowski, M.; Riely, G. J.; Pao, W.; Hussain, S.; Ladanyi, M.; Heelan, R. T.; Kris, M. G.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

Clinical testing for EGFR mutations in non-small cell lung cancer: Single laboratory experience with 253 consecutive cases

Meeting Abstract

Li, A. R.; Riely, G. J.; Zakowski, M. F.; Pao, W.; Pan, Q.; Ma, Y.; Miller, V. A.; Kris, M. G.; Ladanyi, M.
Journal of Molecular Diagnostics (2005)

Fulltext@MSK | Save

Correlation of EGFR and KRAS mutation status, response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and survival with histologic subtypes of adenocarcinoma of the lung